Access cutting-edge hr+/her2-negative breast cancer treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Boston location
Preparing your pre-screening questions…
Access hr+/her2-negative breast cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hr+/her2-negative breast cancer treatment provided free
Check if you qualify for this hr+/her2-negative breast cancer clinical trial in Boston, MA
No-Cost Study Care
Local to Boston
Convenient for MA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria. The main questions it aims to answer are: 1. Phase 1a: what is the maximum tolerated dose and recommended dose for phase 2? 2. Phase 1a: how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day? 3. Phase 1b: how safe and effective is TOS-358 when given with standard of care medicines for HR+HER2- metastatic breast cancer (fulvestrant and CDK4/6i)
Sponsor: Totus Medicines
Yes, this clinical trial (NCT05683418) has an active research site in Boston, MA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hr+/her2-negative breast cancer treatment options in Boston, MA, this clinical trial (NCT05683418) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hr+/her2-negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hr+/her2-negative breast cancer clinical trials near you to find additional studies recruiting in your area.
See all breast cancer clinical trials recruiting in Boston — not just this study.
Browse Breast Cancer Trials in Boston →